{"id":59188,"date":"2020-11-03T20:19:27","date_gmt":"2020-11-03T23:19:27","guid":{"rendered":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/"},"modified":"2020-11-03T20:19:27","modified_gmt":"2020-11-03T23:19:27","slug":"anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19","status":"publish","type":"post","link":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/","title":{"rendered":"Anvisa autoriza prosseguimento de testes com vacina contra a covid-19"},"content":{"rendered":"<p style=\"text-align: justify;\">A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) anunciou hoje (3) que autorizou que o laborat\u00f3rio Janssen-Cilag (divis\u00e3o farmac\u00eautica da Johnson &#038; Johnson) prossiga com as pesquisas da vacina contra a covid-19.<\/p>\n<p style=\"text-align: justify;\">\n<p style=\"text-align: justify;\">O laborat\u00f3rio suspendeu os testes no dia 12 de outubro por causa de um \u201cevento adverso grave\u201d com um volunt\u00e1rio nos Estados Unidos. Segundo a ag\u00eancia, os estudos cl\u00ednicos com a vacina, denominada de<\/p>\n<p style=\"text-align: justify;\">Ad26COVS2.S j\u00e1 podem ser retomados e que a decis\u00e3o desta ter\u00e7a-feira &#8220;garante seguran\u00e7a aos volunt\u00e1rios brasileiros que queiram participar do experimento&#8221;.<\/p>\n<p style=\"text-align: justify;\">Segundo a Anvisa, as regras da pesquisa cl\u00ednica j\u00e1 preveem a ocorr\u00eancia de eventos adversos e que a identifica\u00e7\u00e3o desses epis\u00f3dios serve justamente para conhecer e definir o perfil de seguran\u00e7a de cada medicamento. A ag\u00eancia observou ainda que esses eventos graves exigem a paralisa\u00e7\u00e3o de todo o estudo e a investiga\u00e7\u00e3o do caso antes da retomada da pesquisa.<\/p>\n<p style=\"text-align: justify;\">&#8220;Ap\u00f3s avaliar os dados do evento adverso e as informa\u00e7\u00f5es do Comit\u00ea Independente de Seguran\u00e7a, al\u00e9m de dados da autoridade regulat\u00f3ria norte-americana (Food and Drugs Administration \u2013 FDA), a Anvisa concluiu que a rela\u00e7\u00e3o benef\u00edcio e risco se mant\u00e9m favor\u00e1vel e que o estudo poder\u00e1 ser retomado&#8221;, disse a ag\u00eancia reguladora.<\/p>\n<p style=\"text-align: justify;\">De acordo com a Anvisa, no momento da interrup\u00e7\u00e3o 12 volunt\u00e1rios do Brasil, todos do Rio de Janeiro, j\u00e1 haviam participado do teste, recebendo a dose da vacina ou do placebo. O estudo da Janssen-Cilag<\/p>\n<p style=\"text-align: justify;\">no pa\u00eds est\u00e1 sendo conduzido em 11 estados, com previs\u00e3o de envolver at\u00e9 7.560 pessoas com mais de 18 anos.<\/p>\n<p style=\"text-align: justify;\">&#8220;\u00c9 importante destacar que a Anvisa continuar\u00e1 acompanhando todos os eventos adversos observados durante o estudo e, caso seja identificada qualquer<\/p>\n<p style=\"text-align: justify;\">situa\u00e7\u00e3o grave com volunt\u00e1rios brasileiros, ir\u00e1 tomar as medidas previstas nos protocolos para a investiga\u00e7\u00e3o criteriosa desses eventos&#8221;, disse a ag\u00eancia.<\/p>\n<p style=\"text-align: justify;\">Com informa\u00e7\u00e3o: Ag\u00eancia Brasil<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) anunciou hoje (3) que autorizou que o laborat\u00f3rio Janssen-Cilag (divis\u00e3o farmac\u00eautica da Johnson &#038; Johnson) prossiga com as pesquisas da vacina contra a covid-19. O laborat\u00f3rio suspendeu os testes no dia 12 de outubro por causa de um \u201cevento adverso grave\u201d com um volunt\u00e1rio nos Estados Unidos. Segundo &hellip;<\/p>\n","protected":false},"author":2,"featured_media":59189,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"facebook_2648258775420054_1618374048415101":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":"","_jetpack_memberships_contains_paid_content":false},"categories":[113,384],"tags":[7398,5689,7399,7400],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Anvisa autoriza prosseguimento de testes com vacina contra a covid-19<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa autoriza prosseguimento de testes com vacina contra a covid-19\" \/>\n<meta property=\"og:description\" content=\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) anunciou hoje (3) que autorizou que o laborat\u00f3rio Janssen-Cilag (divis\u00e3o farmac\u00eautica da Johnson &#038; Johnson) prossiga com as pesquisas da vacina contra a covid-19. O laborat\u00f3rio suspendeu os testes no dia 12 de outubro por causa de um \u201cevento adverso grave\u201d com um volunt\u00e1rio nos Estados Unidos. Segundo &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Portal NPM\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-03T23:19:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Genival Barbosa\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Genival Barbosa\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/\",\"url\":\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/\",\"name\":\"Anvisa autoriza prosseguimento de testes com vacina contra a covid-19\",\"isPartOf\":{\"@id\":\"https:\/\/portalnpm.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg\",\"datePublished\":\"2020-11-03T23:19:27+00:00\",\"dateModified\":\"2020-11-03T23:19:27+00:00\",\"author\":{\"@id\":\"https:\/\/portalnpm.com\/#\/schema\/person\/49313e563cfdefcc167f1ee4c017c294\"},\"breadcrumb\":{\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#primaryimage\",\"url\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg\",\"contentUrl\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg\",\"width\":640,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/portalnpm.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa autoriza prosseguimento de testes com vacina contra a covid-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/portalnpm.com\/#website\",\"url\":\"https:\/\/portalnpm.com\/\",\"name\":\"Portal NPM\",\"description\":\"Not\u00edcias em Primeira M\u00e3o\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/portalnpm.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/portalnpm.com\/#\/schema\/person\/49313e563cfdefcc167f1ee4c017c294\",\"name\":\"Genival Barbosa\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/portalnpm.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/02\/avatar_user_2_1707743258-96x96.jpeg\",\"contentUrl\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/02\/avatar_user_2_1707743258-96x96.jpeg\",\"caption\":\"Genival Barbosa\"},\"url\":\"https:\/\/portalnpm.com\/index.php\/author\/genival\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa autoriza prosseguimento de testes com vacina contra a covid-19","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa autoriza prosseguimento de testes com vacina contra a covid-19","og_description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) anunciou hoje (3) que autorizou que o laborat\u00f3rio Janssen-Cilag (divis\u00e3o farmac\u00eautica da Johnson &#038; Johnson) prossiga com as pesquisas da vacina contra a covid-19. O laborat\u00f3rio suspendeu os testes no dia 12 de outubro por causa de um \u201cevento adverso grave\u201d com um volunt\u00e1rio nos Estados Unidos. Segundo &hellip;","og_url":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/","og_site_name":"Portal NPM","article_published_time":"2020-11-03T23:19:27+00:00","og_image":[{"width":640,"height":360,"url":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg","type":"image\/jpeg"}],"author":"Genival Barbosa","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Genival Barbosa","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/","url":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/","name":"Anvisa autoriza prosseguimento de testes com vacina contra a covid-19","isPartOf":{"@id":"https:\/\/portalnpm.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg","datePublished":"2020-11-03T23:19:27+00:00","dateModified":"2020-11-03T23:19:27+00:00","author":{"@id":"https:\/\/portalnpm.com\/#\/schema\/person\/49313e563cfdefcc167f1ee4c017c294"},"breadcrumb":{"@id":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#primaryimage","url":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg","contentUrl":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg","width":640,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/portalnpm.com\/index.php\/2020\/11\/03\/anvisa-autoriza-prosseguimento-de-testes-com-vacina-contra-a-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/portalnpm.com\/"},{"@type":"ListItem","position":2,"name":"Anvisa autoriza prosseguimento de testes com vacina contra a covid-19"}]},{"@type":"WebSite","@id":"https:\/\/portalnpm.com\/#website","url":"https:\/\/portalnpm.com\/","name":"Portal NPM","description":"Not\u00edcias em Primeira M\u00e3o","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/portalnpm.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/portalnpm.com\/#\/schema\/person\/49313e563cfdefcc167f1ee4c017c294","name":"Genival Barbosa","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/portalnpm.com\/#\/schema\/person\/image\/","url":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/02\/avatar_user_2_1707743258-96x96.jpeg","contentUrl":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/02\/avatar_user_2_1707743258-96x96.jpeg","caption":"Genival Barbosa"},"url":"https:\/\/portalnpm.com\/index.php\/author\/genival\/"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/naom_5e85ef9916e79.jpg","_links":{"self":[{"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/posts\/59188"}],"collection":[{"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/comments?post=59188"}],"version-history":[{"count":0,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/posts\/59188\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/media\/59189"}],"wp:attachment":[{"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/media?parent=59188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/categories?post=59188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/tags?post=59188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}